Denali Therapeutics (DNLI) Accounts Payables (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Accounts Payables data on file, last reported at $40.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $40.4 million, up 377.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.4 million (up 377.42% YoY), and the FY2025 annual result was $505000.0, down 95.47% from the prior year.
• Accounts Payables rose to $40.4 million in Q1 2026 per DNLI's latest filing, from $505000.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $40.4 million in Q1 2026 and troughed at $505000.0 in Q4 2025.
• A 5-year average of $9.6 million and a median of $8.5 million in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables soared 435.21% in 2024, then sank 95.47% in 2025.
• A 5-year view of Accounts Payables shows it stood at $2.8 million in 2022, then jumped by 239.89% to $9.5 million in 2023, then grew by 17.44% to $11.1 million in 2024, then slumped by 95.47% to $505000.0 in 2025, then surged by 7896.04% to $40.4 million in 2026.
• Business Quant data shows DNLI's Accounts Payables at $40.4 million in Q1 2026, $505000.0 in Q4 2025, and $6.7 million in Q3 2025.